Nuclear factor B (NF-B) and activator protein 1 (AP-1) are key transcription factors that orchestrate expression of many genes involved in inflammation, embryonic development, lymphoid differentiation, oncogenesis, and apoptosis (48, 62) . NF-B and AP-1 activities are induced by a plethora of physiological and environmental stimuli (5, 51) .
The activity of NF-B is regulated by its interaction with the family of NF-B inhibitors known as IB, which results in the formation of inactive NF-B-IB complexes in the cytoplasm (3, 4, 60) . In response to various stimuli, the IB kinase complex (IKK) then phosphorylates the IB bound to the NF-B complexes as substrates (8, 36, 45, 47) . The subsequent proteasome-mediated degradation of IB exposes the nuclear localization signal (NLS) of NF-B, which releases the NF-B proteins to be translocated to the nucleus, where they regulate the transcription of specific genes (5, 48) .
AP-1 is a group of basic leucine zipper (bZIP) transcription factors consisting of the Fos (c-Fos, FosB, Fra1, and Fra2) and Jun (c-Jun, JunB, and JunD) families (54, 62) . The predominant forms of AP-1 in most cells are Fos/Jun heterodimers which have a high affinity for binding to an AP-1 site, whereas Jun/Jun homodimers bind to the AP-1 site with low affinity (54, 62) . A number of studies have shown that serum and growth factors that induce AP-1 do so by activating the extracellular signal-regulated kinase (ERK) subgroup of mitogen-activated protein kinases (MAPKs) (9, 27, 55) . These activated members of MAPKs translocate to the nucleus to phosphorylate and thereby transcriptionally activate a subfamily of ETS domain transcription factors known as ternary complex factors (TCFs) that bind to fos promoters (9, 27, 55, 65, 80) . fos, fosB, and other members of the AP-1 family of transcription factors are mainly regulated at their transcription through serum responsive elements (SREs) in their promoters (57, 76) . For example, the regulation of c-fos expression is controlled by Elk, a member of TCFs that associates with the serum response factor (SRF) (11, 28, 49) . The elk-1 gene encodes two spliced variants: elk-1 and an alternatively spliced variant known as ⌬elk-1, which is missing the SRF interaction domain and part of the elk-1 DNA binding domain (61) . The ⌬Elk-1protein cannot form an SRF-dependent ternary complex with SRE to activate fos transcription (61) . However, a variety of experiments have shown that Elk-1 proteins play a central role in the response of cells to many extracellular signals and control the expression of genes involved in cell cycle progression, differentiation, and apoptosis (62, 75) . The mechanism by which Elk-1 activates transcription in response to various stimuli has been extensively studied; however, less is known about the regulation of elk-1 gene expression itself.
Even though NF-B and AP-1 transcription factors are regulated by different mechanisms, they appear to be activated simultaneously by the same multitude of stimuli (1, 19, 37, 43, 71, 78) . A number of reports also showed that these transcrip-tion factors appear to be regulated by the same intracellular signal transduction cascades. Indeed, the activation of JNK by inflammatory cytokines or by stress is often accompanied by the nuclear translocation of NF-B, and many genes require the concomitant activation of AP-1 and NF-B, suggesting that these transcription factors work cooperatively (77) . One clue to the interactions between the AP-1 and NF-B activation pathways was the finding that activation of the MAPK pathway leads to the activation of JNK and the IB kinase complexes (42, 43, 83) . In addition, a scaffold protein was discovered that participates in the activation of the JNK pathway and the nuclear translocation of NF-B (69) . Further, the response to AP-1 is strikingly enhanced when NF-B subunits are present and vice versa (66) . The p65 subunit of NF-B can act like an accessory protein for the SRF in transfection assays (20) . NF-B and C/EBP␤ transcription factors are accessory proteins for the RhoA-linked regulation of the activity of the SRF (50) . More recent findings have shown that NF-B and AP-1 play a crucial role in the regulation of FasL in the Fas-mediated thymineless death of colon carcinoma cells (26) . Moreover, the differential binding of AP-1 and NF-B to the interleukin-8 (IL-8) promoter regulates the cell type-specific induction of H 2 O 2 -and tumor necrosis factor alpha (TNF-␣)-mediated IL-8 gene expression (41) . On the basis of these collective findings, one could speculate, therefore, an intriguing possibility that NF-B and AP-1 may modulate the activity of each other, thus expanding the scope of these two rapidly inducible transcription factors. This interesting possibility implies that a cellular response to certain stimuli is induced cooperatively by a network of transcription factors that are activated concurrently. In this study, we delineated the signaling cascades responsible for NF-B-dependent AP-1 regulation and VEGF expression by using cells lacking key components of the NF-B activation pathway. We provided the first evidence that NF-B plays an essential role in regulation of elk-1 expression, which in turn can be activated by ERK to induce the expression of c-fos and fosB in response to certain stimuli.
MATERIALS AND METHODS
Reagents. Doxycycline was purchased from Sigma. A stock solution of 8-mg/ml doxycycline was prepared immediately before its use in phosphate-buffered saline (PBS) with a pH of 7.4. The expression vector encoding IKK2 (S177, 181E), the constitutively active form of IKK2, was described by Schmidt et al. (58) . The expression vectors encoding mutant elk-1 (DN-Elk-1) and fos (⌬Fos) were generated as described by Vanhoutte et al. (74) and Yen et al. (85) , respectively. elk-1 promoter was cloned by PCR into a luciferase reporter gene as previously described (44) . The wild-type and mutated B binding motifs in elk-1 promoter were generated by site-directed mutagenesis performed with a double-stranded, site-directed mutagenesis kit from Stratagene. Primary antibodies for immunoblotting (IB␣, VEGF, and ␤-actin) and the electrophoretic mobility shift assay (EMSA) (RelA/p65, p50, Fos, and Elk-1) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif.) Radioisotopes were purchased from Amersham Biosciences.
Cell culture. Ϫ/Ϫ , and IKK2 Ϫ/Ϫ murine embryonic fibroblast (MEF) cells were provided by Inder M. Verma (Salk Institute, La Jolla, Calif.) (46, 47) . Cells were maintained in plastic flasks as adherent monolayers in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential amino acids, and L-glutamine in 5% CO 2 at 37°C. For doxycycline stimulation, a stock solution of doxycycline (Sigma, The Woodlands, Tex.) was prepared with PBS at 8 mg/ml (pH 7.4) and diluted in PBS to allow a 1% volume addition of doxycycline to the experimental wells. Control cells were treated with a 1% volume of PBS, which is indicated in the figures and figure legends as 0-g/ml doxycycline.
Transfection and luciferase assays. One microgram each of the wild-type B, mutant B, wild-type AP-1, mutant AP-1, wild-type Elk-1, and mutant Elk-1 reporter plasmids containing the firefly luciferase reporter gene (79) and the pRL-TK plasmid, containing the Renilla luciferase gene under the control of the herpes simplex virus thymidine kinase promoter as an internal control, was cotransfected into cells in triplicate by the lipotransfection method (FuGENE 6; Roche, Indianapolis, Ind.) according to the manufacturer's recommendation. The activities of both firefly and Renilla luciferases were determined 48 h after transfection with the dual luciferase reporter assay system (Promega, Madison, Wis.). The luciferase activities were normalized to the Renilla luciferase activity of the internal control.
EMSA. EMSA was performed with nuclear extracts prepared from control and stimulated cells as previously described (17) . Briefly, 10 g of nuclear extract was incubated with 1 g of poly(dI-dC) (Pharmacia, Piscataway, N.J.) in 10 l of binding buffer (75 mM NaCl, 15 mM Tris-HCl, [pH 7.5], 1.5 mM EDTA, 1.5 mM dithiothreitol, 25% glycerol, 20-mg/ml bovine serum albumin) for 40 min at 4°C. 32 P-labeled probes contained the following double-stranded oligonucleotides, which were synthesized by Sigma and generated by a kinase reaction with polynucleotide kinase and [␥-
32 P]ATP (Amersham Pharmacia Biotech, Inc., Piscataway, N.J.) (underlined portions of the sequences represent specific binding sites for the transcription factors; boldface letters represent mutated sites): wild-type B (5Ј-AGTTGAGGGGACTTTCCCAGGC-3Ј), mutant B (5Ј-AGTTGAGG CGACTTTCCCAGGC-3Ј), wild-type AP-1 (5Ј-CGCTTGATGACTCAGCCG GAA-3Ј), mutant AP-1 (5Ј-CGCTTGATGACTTGGCCGGAA-3Ј), Oct-1 (5Ј-T GTCGAATGCAAATCACTAGAA-3Ј), wild-type Elk-1 (5Ј-GGATGTCCATA TTAGGACATCT-3Ј), mutant Elk-1 (5Ј-GGATGTCCATATTATTACATCT-3Ј), wild-type B/Elk-1 (5Ј-GCTCTGTAGGGAAGGGCCCGTCCCC-3Ј), and mutant B/Elk-1 (5Ј-GCTCTGTAGAAAAGGGCGGGTCCCC-3Ј). Equal loading of nuclear extracts was monitored by Oct-1 binding. For competition assays, a 50-fold molar excess of unlabeled oligonucleotides was added to the binding reaction mixture. For supershift assays, 2 l of polyclonal antibodies to p65, p50, p52, c-Rel, Elk-1, and c-Fos (Santa Cruz Biotechnology, Inc.) in the presence or absence of their neutralizing peptides were preincubated for 30 min with the nuclear extracts before the probe was added. The probe was allowed to bind for 20 min at room temperature. Reaction mixtures were analyzed on 4% polyacrylamide gels containing 0.25ϫ TBE (22.5 mM Tris, 22.5 mM borate and 500 M EDTA, pH 8.0) buffer. The gel was then dried for 1 h at 80°C and exposed to Kodak film (Eastman Kodak Co., Rochester, N.Y.) at Ϫ80°C.
Northern blot analysis. For Northern blot analysis, total RNA was extracted with Trizol reagent (Life Technologies, Inc., Gaithersburg, Md.) according to the manufacturer's recommendation. Fifteen micrograms of total RNA was separated electrophoretically on a 1% denaturing formaldehyde-agarose gel, transferred to a Hybond nylon filter (MSI, Westborough, Mass.) in 20ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 N sodium citrate), and UV cross-linked with a UV Stratalinker 1800 (Stratagene, La Jolla, Calif.). To obtain a cDNA probe for the Northern blot, reverse transcription-PCR was performed as follows. One microgram of total RNA made from MDAPanc-28 cells was reverse transcribed at 42°C for 1 h in the presence of 100 ng of Oligo (dT) 12-18 primer (Life Technologies, Inc.), 250 M deoxynucleoside triphosphates (dNTPs; Promega), 1ϫ incubation buffer of avian myeloblastosis virus (AMV) reverse transcriptase (Roche), 20 U of RNase inhibitor (Roche), and 25 U of avian myeloblastosis virus reverse transcriptase (Roche) in a final volume of 20 l. One microliter of the reaction mixture was then subjected to 30 PCR cycles (denaturing at 94°C for 1 min, annealing at 56°C for 1 min, and polymerization at 72°C for 1 min) in the presence of 0.25 U of Taq DNA polymerase (Roche), 1ϫ PCR buffer (Roche), 250 M dNTPs (Promega), and 500 nM specific primers as follows: human Elk-1 (product size, 941 bp; 5Ј-TCCTTCTCCAGCATGGGCTC-3Ј and 3Ј-TCAGCC TCGGGGTAGGTGAA-5Ј); and mouse Elk-1 (product size, 900 bp; 5Ј-TCCT TCTCCAGCATGGGCTC-3Ј and 3Ј-TCAGCCTCGGGGTAGGTGAA-5Ј). PCR products were extracted and subsequently cloned in a pCR2.1-TOPO vector (Invitrogen, Carlsbad, Calif.) for sequence analysis. The sequences of these cDNA fragments agreed with those from the GenBank database. The cDNA probes (EcoRI-EcoRI) were labeled with [␣-
32 P]dCTP with the Roche random labeling kit and subjected to hybridization. Equal loading of mRNA samples was monitored by hybridizing the same membrane filter with the cDNA probe for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as described previously (32) .
RNase protection assay. RNA was isolated from wild-type, IKK1 Ϫ/Ϫ , and IKK2 Ϫ/Ϫ MEF cells stimulated with either doxycycline or 20% serum for the indicated dose and time, using Trizol reagent. An RNase protection assay was VOL. 24, 2004 AP-1 REGULATION BY NF-B-DEPENDENT Elk-1 EXPRESSION 7807 performed with the Riboquant multiprobe protection assay system according to the manufacturer's recommendation. Western blot analysis. Cytoplasmic extracts were prepared as previously described (17) . Soluble protein was separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (10% polyacrylamide) and electrophoretically transferred onto polyvinylidene difluoride membrane (Osmonics, Westborough, Mass.). The membrane was blocked with 5% nonfat milk in PBS containing 0.2% Tween 20 and incubated with affinity-purified mouse antibody to IB␣, c-Fos, and ␤-actin (Santa Cruz Biotechnology, Inc.). The membranes were washed in PBS containing 0.2% Tween 20 and probed with horseradish peroxidase-coupled secondary goat anti-rabbit or anti-mouse immunoglobulin G antibodies (Amersham, Arlington Heights, Ill.). The proteins were detected with the Lumi-Light Western blotting substrate (Roche) according to the manufacturer's instructions.
ChIP assay. The chromatin immunoprecipitation (ChIP) assay was performed with a chromatin immunoprecipitation assay kit (Upstate Biotechnology, Lake Placid, N.Y.) as recommended by the manufacturer. Briefly, after MDAPanc28/ puro and MDAPanc28/IB␣M cells (2 ϫ 10 6 each) were stimulated with 40-g/ml doxycycline for 24 h, formaldehyde (1% final concentration) was directly added to the culture medium for cross-linked reactions at 37°C for 10 min. Cells were lysed in 200 l of SDS lysis buffer with a protease-inhibitor mixture and sonicated to generate DNA fragments 200 to 1,000 bp long. After a preclearing step for 30 min at 4°C, the lysates were incubated with anti-p65 antibody (Santa Cruz) at 4°C for overnight with rotation. Immune complexes were precipitated with 60 l of salmon sperm DNA-protein A agarose, eluted with elution buffer (1% SDS, 0.1 M NaHCO 3 ) after washing, and incubated at 65°C for 6 h. After proteinase K (20 g/ml) digestion at 50°C for 2 h, DNA was extracted in phenol, precipitated with ethanol, resuspended in 20 l of Tris-EDTA (TE) buffer, and subjected to PCR, using for elk-1 primers 5Ј-CGTTCCATCATTTCCCCTTA-3Ј and 5Ј-TGCGTTTCCCTACAGCTCAC-3Ј, which corresponded to 167 bp of the elk-1 promoter region, including the predicted NF-B binding site.
RESULTS

Blocking constitutive NF-B activation inhibits AP-1 activity and the overexpression of c-fos.
To determine whether constitutive NF-B activity and AP-1 activity were coupled, NF-B and AP-1 activities were analyzed in MDAPanc-28/ IB␣M and MDAPanc-28/Puro cells established from pooled Flag-tagged IB␣M-infected and puromycin control retrovirus-infected MDAPanc-28 cells (22, 23) . The expression of the Flag-IB␣M protein was confirmed by Western blot analysis (Fig. 1A) . In MDAPanc-28/IB␣M cells, the constitutive DNA binding activity of RelA/p50 heterodimer was also completely inhibited, and the constitutive AP-1-DNA binding activity was concurrently downregulated significantly, whereas the Oct-1 DNA binding activity was not altered (Fig. 1A) .
To elucidate the mechanism underlying the inhibition of AP-1 activation by the IB␣M-mediated suppression of constitutive NF-B activity, we first examined the transcriptional regulation of the c-fos gene, which encodes a major AP-1 component. Northern blot analysis showed that the overexpression of c-fos was significantly downregulated in response to IB␣M-mediated NF-B inhibition (Fig. 1A) . This finding was consistent with the significant inhibition of NF-B-and AP-1-dependent reporter gene activities in the MDAPanc-28/ IB␣M cells ( Ϫ/Ϫ cells ( Fig. 3A and B) . The partial inhibition of serum-induced AP-1 activity in IKK1 Ϫ/Ϫ MEF cells ( Fig. 3E , AP-1 DNA binding activity was induced by PMA, IL-1␣, and TNF-␣ in wild-type but not in IKK2 Ϫ/Ϫ cells. Taken together, these results suggest that NF-B activation is one of the regulatory steps for AP-1 in response to several inducers such as serum, ROS, and cytokines.
To determine which AP-1 component is expressed and induced by doxycycline and serum, RNase protection assays were performed with wild-type, IKK1
Ϫ/Ϫ , and IKK2 Ϫ/Ϫ MEF cells. Doxycycline stimulation induced the dose-dependent gene expression of c-jun, junB, c-fos, fosB, fra-1, and fra-2, but not junD, in wild-type MEF cells (Fig. 4A) . However, the doxycycline-induced expression of c-jun, junB, c-fos, fosB, fra-1, and fra-2 was reduced and delayed in IKK1
Ϫ/Ϫ cells, and expression of c-fos and fosB genes was not detected in IKK2
Ϫ/Ϫ cells (Fig. 4A) . c-jun expression was even elevated in IKK2 Ϫ/Ϫ MEF cells (Fig. 4A) . These results suggest that the regulation of the expression of c-jun, junB, fra-1, and fra-2 partially depends on IKK under doxycycline stimulation and that IKK2 activity is required for doxycycline to mediate c-fos and fosB expression.
The induced expression of c-jun, junB, junD, c-fos, and fosB peaked from 15 to 30 min after serum stimulation, and the induction of fra-1 and fra-2 expression peaked at 60 min after serum stimulation in wild-type MEF cells (Fig. 4B) . The serum induction of c-jun, junB, junD, c-fos, fosB, fra-1, and fra-2 gene expression decreased to some extent in IKK1
Ϫ/Ϫ cells, consistent with serum-induced AP-1 DNA binding activity (Fig. 3B) . In contrast, the serum-induced expression of c-jun, junB, junD, c-fos, fosB, fra-1, and fra-2 was considerably reduced and delayed in IKK2 Ϫ/Ϫ MEF cells (Fig. 4B) , consistent with the inhibition of AP-1 activation (Fig. 3B) . Only the reduction and delay of c-fos and fosB induction by serum stimulation were observed in IKK2
Ϫ/Ϫ cells, as opposed to the complete inhibition of fos and fosB induction by doxycycline stimulation (Fig.  4A) . Serum-induced c-jun expression was not affected in IKK1 Ϫ/Ϫ MEF cells and was even sustained in IKK2 Ϫ/Ϫ MEF cells, consistent with findings of a previous study (68) . These results suggest that, under serum stimulation, IKK2 but not IKK1 is involved in the regulation of the expression of AP-1 components. Taken together, these results suggest that NF-B plays an important role in the regulation of the expression of c-fos and fosB in response to doxycycline stimulation but plays a less prominent role in the serum-regulated expression of c-fos and fosB.
NF-B regulates elk-1 expression. Because the SRE appears to be constitutively occupied in vivo, increased Elk-1 transcriptional activity is a more likely mechanism of c-fos induction (9, 25, 29, 35, 73) . Therefore, we speculated that NF-B-dependent elk-1 expression might play an important role in augmenting c-fos expression and in AP-1 induction in response to doxycycline stimulation. Our data ( Fig. 1 to 4) suggest that the regulation of c-fos expression is a key step by which NF-B regulates AP-1 activity. To determine whether NF-B regulates elk-1 expression, we first analyzed NF-B DNA binding activity to the B-like motif found in the elk-1 promoter (B elk-1 ) (44). We found that the constitutive DNA binding activity of the RelA/p50 heterodimer to the B elk-1 motif was significantly reduced in MDAPanc-28/IB␣M cells (Fig. 5A) . Consistent with this, expression of elk-1 mRNA and Elk-1 DNA binding activity to the SRE also decreased in MDAPanc-28/IB␣M cells ( Fig. 5B and C) . Similar decreases in Elk-1 DNA binding activity and the expression of elk-1 mRNA were observed in IKK1 Ϫ/Ϫ and IKK2 Ϫ/Ϫ MEF cells (Fig. 5D ). Elk-1 activity in MDAPanc-28/Puro and in wild-type MEF cells was determined by competition and supershift assay (Fig. 5E and  F ). To further demonstrate that elk-1 is an NF-B downstream target gene, we performed ChIP assays. The results showed that p65 (NF-B) directly interacted with the promoter region of elk-l in MDAPanc-28/Puro cells, but this interaction was inhibited in MDAPanc-28/IB␣M cells (Fig. 5G) . These results from NF-B EMSA and ChIP assays suggest that NF-B is one of the transcription factors that regulate elk-1 expression.
Induction of elk-1 expression by doxycycline and serum is dependent on NF-B activity. To determine whether the induction of elk-1 expression by doxycycline and serum is dependent on NF-B activity, doxycycline-and serum-induced elk-1 expression and Elk-1 DNA binding activity were analyzed in MDAPanc-28/Puro and MDAPanc-28/IB␣M cells. NF-B DNA binding activity to B elk-1 was inhibited in MDAPanc-28/IB␣M cells, suggesting that the doxycycline-mediated induction of elk-1 expression and DNA binding activity was NF-B dependent ( Fig. 6A and B) . The serum-induced DNA binding activity of NF-B to the B binding site in the elk-1 promoter was detected in MDAPanc-28/Puro cells but was completely inhibited in MDAPanc-28/IB␣M cells (Fig. 6B) . The serum-induced expression of elk-1 and the DNA binding activity of Elk-1 were decreased in MDAPanc-28/IB␣M cells. The Elk-1 DNA binding activity induced by doxycycline and serum was inhibited in IKK1 Ϫ/Ϫ and IKK2 Ϫ/Ϫ MEF cells ( Fig.  7A and B) . Figure 7C shows that overexpression of a constitutively active IKK2 (S177, 181E), IKK2, and p65 (NF-B) by transient transfection of wild-type MEF cells induced the DNA binding activity of RelA/p50 (NF-B), Elk-1, and AP-1 and expression of c-fos and VEGF. IKK2 expression was reconstituted in IKK2 Ϫ/Ϫ cells by establishing stable transfectants (Fig.  7D) . The serum-and doxycycline-induced Elk-1 DNA binding activity and expression of c-fos and VEGF were restored in IKK2-reconstituted cells (Fig. 7E and F) . Furthermore, over- (Fig. 7G) . Collectively, these results imply that the regulation of elk-1 and c-fos expression is NF-B dependent.
NF-B participates the regulation of the elk-1 promoter. To further investigate the regulation of elk-1 expression by NF-B, elk-1 promoters with wild-type and mutated B binding motifs were cloned by PCR into a luciferase reporter gene as previously described (Fig. 8A) (44) . The luciferase reporter gene reporter gene activity of the elk-1 promoter was significantly decreased in MDAPanc-28/IB␣M cells and IKK1
Ϫ/Ϫ and IKK2 Ϫ/Ϫ MEF cells (Fig. 8B) . Doxycycline-mediated elk-1 promoter reporter gene activity was induced in MDAPanc-28/ Puro cells but almost completely inhibited in MDAPanc-28/ IB␣M cells (Fig. 8C) . These results suggest that elk-1 is one of the downstream target genes regulated by NF-B in response to doxycycline stimulation. To determine the role of Elk-1 in doxycycline-mediated AP-1 activation, AP-1-dependent luciferase reporter gene activity was analyzed in MDAPanc-28/ Puro cells transfected with or without a dominant-negative mutant Elk-1 (⌬Elk-1) in the presence or absence of doxycycline. As shown in Fig. 8D , ⌬Elk-1 completely inhibited constitutive (lanes 4 and 5) and doxycycline-induced (lanes 8 and 9) activation of the AP-1 reporter gene, indicating that Elk-1 plays an essential role in both constitutive and doxycyclineinducible AP-1 activity.
NF-B-dependent AP-1 activity regulates VEGF expression. We and others have previously shown that the inhibition of NF-B suppressed tumorigenesis and metastasis and downregulated VEGF expression in a number of cancer cell lines (6, 22, 23, 30, 38, 63) . However, analysis of the VEGF regulation showed that several AP-1 and hypoxia-induced factor (HIF) elements, not the B site present in the VEGF promoter and AP-1 and HIFs regulate VEGF expression (24, 56, 64, 70) . We further analyzed NF-B-mediated VEGF expression in Panc28/Puro and Panc28/IB␣M cells. The inhibition of constitutive NF-B activity by IB␣M downregulated VEGF expression and VEGF promoter activity ( Fig. 9A and B) . IB␣M-mediated inhibition of NF-B also completely suppressed doxycycline-induced VEGF expression (Fig. 9C) . Downregulated serum-induced VEGF levels were also observed in MDAPanc-28/IB␣M cells (Fig. 9D) . Interestingly, the transient induction of VEGF expression induced by serum occurred in early and late phases at 30 and 180 min. The early phase coincided with serum-induced transient c-fos expression, which peaked at 30 min, and the late phase overlapped with the appearance of delayed AP-1 activation, which occurred at 180 and 360 min (Fig. 2B) . These results suggest that NF-B- To determine whether NF-B-dependent AP-1 activity regulates the VEGF promoter, Panc-28/Puro cells were transfected with a VEGF promoter-luciferase reporter gene construct and various combinations of the expression vectors encoding IB␣M, dominant-negative Fos mutant (⌬Fos), Fos, FosB, JunB, JunD, and c-Jun (Fig. 9E) . These results showed that the VEGF promoter activity induced by the constitutive NF-B activity in Panc28/Puro cells was inhibited by IB␣M and ⌬Fos, and IB␣M-mediated inhibition of VEGF promoter activity was overcome by cotransfection and overexpression of the c-fos gene (Fig. 9E) . Furthermore, VEGF promoter-luciferase reporter gene assays showed that c-Fos is a more potent activator of VEGF promoter than other members of AP-1 family (Fig. 9E) . These findings are consistent with the results shown in previous figures and suggest that NF-B-regulated AP-1 activity induced VEGF expression.
DISCUSSION
Our results showed that the inhibition of NF-B activity, achieved by stable expression of IB␣M in MDAPanc-28 cells or by MEF cells lacking IKK1 or IKK2, led to the inhibition of fos expression and AP-1 activity. We found that elk-1 was one of the NF-B downstream genes. Inhibition of NF-B reduced the level of Elk-1 protein to be activated by MAPK, thus impeding AP-1 activity and AP-1-dependent gene expression. We further found that the expression of VEGF, which possesses AP-1 binding motifs but not NF-B in its promoter, was significantly downregulated in IB␣M transfectants (Fig. 9A  and B) . Previous studies also suggested that NF-B regulates VEGF gene expression at the transcriptional level (22, 23, 31, 38, 63) . Our results also showed that the constitutive and inducible NF-B activities played key roles in upregulating the transcription of its downstream gene elk-1. The increased level of MAPK-activated Elk-1 further induced c-fos expression and AP-1 activity, which in turn increased VEGF gene expression. Thus, our findings provide a possible mechanism by which NF-B regulates VEGF expression through Elk-1 and AP-1.
Transcription factors serve as integration centers of the different signaling cascades that control the expression of a given gene. The regulation of these transcription factors themselves is therefore of critical importance in determining the response to various physiological and environmental stimuli. Transcription factors can be regulated mainly by two means-concentration and activity-each of which can be modulated in diverse ways. For example, the activity of a transcription factor is often regulated by phosphorylation or dephosphorylation through multiple intracellular signal transduction pathways. The MAPKs are mediators of signal transduction from the cell surface to the nucleus, and NF-B, Elk-1 and AP-1 are the targets of these MAPKs. For example, MAPK kinase kinase-3 (MEKK3), a mammalian serine/threonine kinase that directly activates JNKK1, a MAPK kinase that stimulates JNK1/2 and p38 MAPK, which in turn induces AP-1, has been shown to activate IKK1 and IKK2 in TNF-␣-induced NF-B activation (12, 18, 83, 86) . In this way, two distinct transcription factors, NF-B and AP-1, could be cooperatively regulated by MAPK signaling cascades, the activation of NF-B could lead an increase in the transcription of elk-1 and c-fos, and the activation of Erk1/2, p38, and JNK could enhance the activity of Elk-1 and AP-1 transcription factors.
The coactivation of NF-B and AP-1 can synergistically and effectively enhance the transcription of genes in response to a variety of stimuli. Many genes require the simultaneous acti- (66) . This seems to explain one mechanism of cross talk between these distinct transcription factors. In our study, we initially found that the level of c-fos expression was significantly decreased in Panc-28/IB␣M cells, in which constitutive NF-B activity was inhibited (Fig. 1A) . Consistent with this, the transcription of junB, c-fos, fosB, and fra-2 genes was downregulated in MEF cells lacking IKK1 or IKK2 (Fig. 4A and B) . These results led us to hypothesize that the transcriptional downregulation of AP-1 components, especially c-Fos, might play an important role in the regulation of NF-B-dependent AP-1 downstream target genes. In our experiments, we used serum and doxycycline, which strongly induces both NF-B and AP-1 activities through the generation of superoxide (unpublished data). Under doxycycline stimulation, most AP-1 components were induced at the transcriptional level in wild-type MEF cells, but less so in IKK1 Ϫ/Ϫ cells, suggesting a general role for IKK1 in the regulation of AP-1 components stimulated by doxycycline (Fig. 4A) . However, the inducible c-Fos and FosB were specifically inhibited, while the expression of other AP-1 components in IKK2 Ϫ/Ϫ MEF cells was only weakly inhibited, suggesting that IKK2 is the key effector in the regulation of AP-1 by exerting specific control over the transcription of c-fos and fosB under doxycycline stimulation (Fig. 4A) . However, under serum stimulation, c-fos and fosB expression in IKK2 Ϫ/Ϫ cells was only weakly inhibited ( Fig. 4B) , suggesting the effect of IKK in the regulation of the specific AP-1 monomer is signal dependent. The inhibition of constitutive and inducible c-fos expression resulted in the downregulation of AP-1 activity and the expression of AP-1-regulated genes such as VEGF (Fig. 9) .
To further clarify the mechanism by which NF-B regulates the expression of c-fos, we determined the activity of Elk-1, a transcription factor that regulates c-fos transcription (28, 33, 72) . We showed that the expression of elk-1 was transcriptionally regulated by NF-B through an NF-B-like binding motif in the elk-1 promoter and that the doxycycline-induced activation of the RelA/p65 heterodimer to this motif was significantly reduced in IB␣M-expressing cells (Fig. 5 and 6 ), which in turn inhibited the expression of elk-1, which decreased the level of Elk-1 protein that can be activated by MAPKs and the binding of Elk-1 to its binding motif in the c-Fos promoter (Fig. 8) . In both IKK1-and IKK2-null cells, the expression level of Elk-1 was greatly reduced; however, it is unclear why only in IKK2 Ϫ/Ϫ cells is the expression of c-fos and fosB predominantly inhibited. It is possible that IKK2 may be involved in regulation other members of the SRFs in addition to Elk-1.
Both Rac and p67 phox are essential for the membrane-bound NADPH oxidase for the generation of superoxide (2, 16, 59) . p67 phox , which consists of two SH3 domains and has no catalytic activity, is a target of Rac (16) . Overexpression of Rac induced the formation of ROS, and this may in part account for Rac-mediated NF-B activation (67) . Another target of Rac is POSH, which contains four SH3 domains (69) . Overexpression of POSH induces both JNK and NF-B activation (69) . POSH interacts with JNK1 and -2, thus, appearing to act (81) . Interestingly, the two C-terminal SH3 domains are sufficient to induce NF-B translocation, but not JNK activation (67) . It is possible that POSH may play a role in increasing JNK and NF-B activities through the interaction of these four SH3 domains with different protein complexes. However, the mechanism by which POSH as a scaffold for multiprotein complexes enhances the specificity of either the JNK or NF-B pathway is not clear. In many cases, JNK and NF-B are activated by same signaling pathways (12, 67, 82, 83) , and the cross talk between these two pathways has been shown. Our findings show that NF-B positively modulates the expression of c-Fos and AP-1 activity. Other findings showed that NF-B could inhibit JNK signaling pathway (14, 52, 53, 68) . For example, NF-B activated Gadd45␤, which in turn associated with MKK7 directly and blocked its further activation of JNK in response to TNF-␣ stimulation (14, 52) . A recent report by Tang et al. suggested that in response to TNF-␣, but not IL-1, X-chromosomelinked inhibitor of apoptosis (XIAP), an NF-B downstream target gene, participated in the suppression of JNK signaling by NF-B (68). Inactivation of JNK by NF-B has been suggested to be a mechanism for the antiapoptotic effect of NF-B upon TNF-␣ stimulation (14, 34, 68) because the JNK-dependent pathway has been shown to be required for TNF-␣-in- duced apoptosis (13) . There seem to be highly specific ways cross talk enables NF-B activity to positively or negatively regulate JNK/AP-1 activities in response to different stimuli, such as TNF-␣, serum, and superoxide. However, it is unclear how activation of both NF-B and JNK pathways in cells achieves a response under different circumstances. In summary, we have discovered a possible mechanism by which NF-B regulates the expression of c-Fos and AP-1 activity through the controlling the expression level of Elk-1. When NF-B and AP-1 are simultaneously activated by many inducers, the increased level of NF-B downstream target gene elk-1 can be further activated by Erk1/2, p38, and JNK for greater induction of fos expression and AP-1 activation, which sequentially enhances the expression of AP-1 downstream target genes, thus allowing multiple regulatory steps and maximal target gene expression in response to a variety of stimuli.
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